Integrated multi-omics approach identified molecular mechanism and pathogenetic processes of COVID-19 that affect patient with Parkinson’s disorder

02, August 2021 |

Authors:

Abstract

The novel coronavirus named SARS-CoV-2 has emerged at the end of 2019, which causes coronavirus dis- ease (COVID-2019). Recent case reports of COVID-19 patients have revealed the onset of Parkinson’s dis- ease (PD) symptoms in patients who do not have a family history of the PD. However, till recently, no genetic impact or mechanisms that may induce Parkinsonism in COVID-19 patients or after COVID-19 have been found.. This study aimed to detect the commonly dysregulated genes, transcriptional regula- tors, and pathways between PD and COVID-19. We integrated genome-wide transcriptomic datasets from peripheral blood mononuclear cells (PBMC) samples from COVID-19 and PD and associated pathways. Our study revealed 81 upregulated and 48 downregulated differentially expressed genes (DEGs) shared between PD and COVID-19. These dysregulated genes were involved in key pathways ‘‘mitochondrion structure organization”, ‘‘cell activation in immune response”, and ‘‘signalling by interleukins”. Our anal- ysis showed RELA, TP53 and SP1 TFs that may regulate the upregulated DEGs. We have discovered key dysregulated genes and characterized the biological processes of commonly dysregulated in COVID-19 and PD, which could be used for the design of personalized treatment of PD following COVID-19.